2018 to 2025 saw rise in GLP-1 receptor agonist Rx for bariatric surgery-eligible patients

Among patients eligible for metabolic and bariatric surgery (MBS), glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescriptions increased from 2018 to 2025, while MBS use decreased beginning in 2023, according to a research letter published online March 4 in JAMA Surgery.

🔗 Read more: https://medicalxpress.com/news/2026-03-glp-receptor-agonist-rx-bariatric.html

#News #Health #Science